Inhibition of c-Myc by let-7b mimic reverses mutidrug resistance in gastric cancer cells. 2015

Xiaojun Yang, and Hui Cai, and Yuhe Liang, and Lin Chen, and Xiangdong Wang, and Ruohuang Si, and Kunpeng Qu, and Zebin Jiang, and Bingqiang Ma, and Changfeng Miao, and Jing Li, and Bin Wang, and Peng Gao
Department of General Surgery, Gansu Provincial Hospital, Lanzhou, Gansu 730000, P.R. China.

Chemotherapy is one of the few effective choices for patients with advanced or recurrent gastric cancer (GC). However, the development of mutidrug resistance (MDR) to cancer chemotherapy is a major obstacle to the effective treatment of advanced GC. Additionally, the mechanism of MDR remains to be determined. In the present study, we tested IC50 of cisplatin (DDP), vincristine (VCR) and 5-fluorouracil (5-FU) in SGC7901, SGC7901/DDP and SGC7901/VCR gastric cancer cells using an MTT assay. The expression of let-7b and c-Myc in these cells was detected by qPCR and western blot analysis. The relationship between let-7b and c-Myc was explored using a luciferase reporter assay. Transfection of let-7b mimic or inhibitor was used to confirm the effect of let-7b on drug sensitivity in chemotherapy via the regulation of c-Myc expression. We found that the expression of let-7b was lower in chemotherapy-resistant SGC7901/DDP and SGC7901/VCR gastric cancer cells than that in chemotherapy-sensitive SGC7901 cells. By contrast, the expression of c-Myc was higher in SGC7901/DDP and SGC7901/VCR cells than that in SGC7901 cells. Furthermore, we confirmed that let-7b suppresses c-Myc gene expression at the mRNA and protein levels in a sequence-specific manner, while transfection of let-7b mimic increases drug sensitivity in chemotherapy-resistant SGC7901/DDP and SGC7901/VCR cells by targeting downregulation of c-Myc. In SGC7901 drug-sensitive cells, however, the sensitivity of chemotherapy was significantly decreased following let-7b inhibitor transfection. The present study results demonstrated that let-7b increases drug sensitivity in chemotherapy‑resistant SGC7901/DDP and SGC7901/VCR gastric cancer cells by targeting the downregulation of c-Myc and that, let-7b mimic reverses MDR by promoting cancer stem cell differentiation controlled by double-negative autoregulatory loops (Lin28/let-7 and Myc/let-7) and a double-positive autoregulatory loop (Lin28/Lin28B/Myc) existing in GC cells, which remains to be confirmed.

UI MeSH Term Description Entries
D009363 Neoplasm Proteins Proteins whose abnormal expression (gain or loss) are associated with the development, growth, or progression of NEOPLASMS. Some neoplasm proteins are tumor antigens (ANTIGENS, NEOPLASM), i.e. they induce an immune reaction to their tumor. Many neoplasm proteins have been characterized and are used as tumor markers (BIOMARKERS, TUMOR) when they are detectable in cells and body fluids as monitors for the presence or growth of tumors. Abnormal expression of ONCOGENE PROTEINS is involved in neoplastic transformation, whereas the loss of expression of TUMOR SUPPRESSOR PROTEINS is involved with the loss of growth control and progression of the neoplasm. Proteins, Neoplasm
D002454 Cell Differentiation Progressive restriction of the developmental potential and increasing specialization of function that leads to the formation of specialized cells, tissues, and organs. Differentiation, Cell,Cell Differentiations,Differentiations, Cell
D002945 Cisplatin An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle. Platinum Diamminodichloride,cis-Diamminedichloroplatinum(II),cis-Dichlorodiammineplatinum(II),Biocisplatinum,Dichlorodiammineplatinum,NSC-119875,Platidiam,Platino,Platinol,cis-Diamminedichloroplatinum,cis-Platinum,Diamminodichloride, Platinum,cis Diamminedichloroplatinum,cis Platinum
D005472 Fluorouracil A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid. 5-FU,5-FU Lederle,5-FU Medac,5-Fluorouracil,5-Fluorouracil-Biosyn,5-HU Hexal,5FU,Adrucil,Carac,Efudex,Efudix,Fluoro-Uracile ICN,Fluoroplex,Fluorouracil Mononitrate,Fluorouracil Monopotassium Salt,Fluorouracil Monosodium Salt,Fluorouracil Potassium Salt,Fluorouracil-GRY,Fluorouracile Dakota,Fluorouracilo Ferrer Far,Fluoruracil,Fluracedyl,Flurodex,Haemato-FU,Neofluor,Onkofluor,Ribofluor,5 FU Lederle,5 FU Medac,5 Fluorouracil,5 Fluorouracil Biosyn,5 HU Hexal,Dakota, Fluorouracile,Fluoro Uracile ICN,Fluorouracil GRY,Haemato FU
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D012333 RNA, Messenger RNA sequences that serve as templates for protein synthesis. Bacterial mRNAs are generally primary transcripts in that they do not require post-transcriptional processing. Eukaryotic mRNA is synthesized in the nucleus and must be exported to the cytoplasm for translation. Most eukaryotic mRNAs have a sequence of polyadenylic acid at the 3' end, referred to as the poly(A) tail. The function of this tail is not known for certain, but it may play a role in the export of mature mRNA from the nucleus as well as in helping stabilize some mRNA molecules by retarding their degradation in the cytoplasm. Messenger RNA,Messenger RNA, Polyadenylated,Poly(A) Tail,Poly(A)+ RNA,Poly(A)+ mRNA,RNA, Messenger, Polyadenylated,RNA, Polyadenylated,mRNA,mRNA, Non-Polyadenylated,mRNA, Polyadenylated,Non-Polyadenylated mRNA,Poly(A) RNA,Polyadenylated mRNA,Non Polyadenylated mRNA,Polyadenylated Messenger RNA,Polyadenylated RNA,RNA, Polyadenylated Messenger,mRNA, Non Polyadenylated
D012334 RNA, Neoplasm RNA present in neoplastic tissue. Neoplasm RNA
D013274 Stomach Neoplasms Tumors or cancer of the STOMACH. Cancer of Stomach,Gastric Cancer,Gastric Neoplasms,Stomach Cancer,Cancer of the Stomach,Gastric Cancer, Familial Diffuse,Neoplasms, Gastric,Neoplasms, Stomach,Cancer, Gastric,Cancer, Stomach,Cancers, Gastric,Cancers, Stomach,Gastric Cancers,Gastric Neoplasm,Neoplasm, Gastric,Neoplasm, Stomach,Stomach Cancers,Stomach Neoplasm
D014162 Transfection The uptake of naked or purified DNA by CELLS, usually meaning the process as it occurs in eukaryotic cells. It is analogous to bacterial transformation (TRANSFORMATION, BACTERIAL) and both are routinely employed in GENE TRANSFER TECHNIQUES. Transfections
D014750 Vincristine An antitumor alkaloid isolated from VINCA ROSEA. (Merck, 11th ed.) Leurocristine,Citomid,Farmistin,Oncovin,Oncovine,Onkocristin,Vincasar,Vincasar PFS,Vincristin Bristol,Vincristin medac,Vincristine Sulfate,Vincrisul,Vintec,cellcristin,PFS, Vincasar,Sulfate, Vincristine

Related Publications

Xiaojun Yang, and Hui Cai, and Yuhe Liang, and Lin Chen, and Xiangdong Wang, and Ruohuang Si, and Kunpeng Qu, and Zebin Jiang, and Bingqiang Ma, and Changfeng Miao, and Jing Li, and Bin Wang, and Peng Gao
December 2018, Cancer gene therapy,
Xiaojun Yang, and Hui Cai, and Yuhe Liang, and Lin Chen, and Xiangdong Wang, and Ruohuang Si, and Kunpeng Qu, and Zebin Jiang, and Bingqiang Ma, and Changfeng Miao, and Jing Li, and Bin Wang, and Peng Gao
July 2019, Cancer gene therapy,
Xiaojun Yang, and Hui Cai, and Yuhe Liang, and Lin Chen, and Xiangdong Wang, and Ruohuang Si, and Kunpeng Qu, and Zebin Jiang, and Bingqiang Ma, and Changfeng Miao, and Jing Li, and Bin Wang, and Peng Gao
May 2012, The American journal of the medical sciences,
Xiaojun Yang, and Hui Cai, and Yuhe Liang, and Lin Chen, and Xiangdong Wang, and Ruohuang Si, and Kunpeng Qu, and Zebin Jiang, and Bingqiang Ma, and Changfeng Miao, and Jing Li, and Bin Wang, and Peng Gao
January 2020, Journal of drug targeting,
Xiaojun Yang, and Hui Cai, and Yuhe Liang, and Lin Chen, and Xiangdong Wang, and Ruohuang Si, and Kunpeng Qu, and Zebin Jiang, and Bingqiang Ma, and Changfeng Miao, and Jing Li, and Bin Wang, and Peng Gao
April 2015, Cancer gene therapy,
Xiaojun Yang, and Hui Cai, and Yuhe Liang, and Lin Chen, and Xiangdong Wang, and Ruohuang Si, and Kunpeng Qu, and Zebin Jiang, and Bingqiang Ma, and Changfeng Miao, and Jing Li, and Bin Wang, and Peng Gao
February 2012, Cancer letters,
Xiaojun Yang, and Hui Cai, and Yuhe Liang, and Lin Chen, and Xiangdong Wang, and Ruohuang Si, and Kunpeng Qu, and Zebin Jiang, and Bingqiang Ma, and Changfeng Miao, and Jing Li, and Bin Wang, and Peng Gao
January 2021, Cancer science,
Xiaojun Yang, and Hui Cai, and Yuhe Liang, and Lin Chen, and Xiangdong Wang, and Ruohuang Si, and Kunpeng Qu, and Zebin Jiang, and Bingqiang Ma, and Changfeng Miao, and Jing Li, and Bin Wang, and Peng Gao
November 2020, Anti-cancer drugs,
Xiaojun Yang, and Hui Cai, and Yuhe Liang, and Lin Chen, and Xiangdong Wang, and Ruohuang Si, and Kunpeng Qu, and Zebin Jiang, and Bingqiang Ma, and Changfeng Miao, and Jing Li, and Bin Wang, and Peng Gao
August 2015, Molecular medicine reports,
Xiaojun Yang, and Hui Cai, and Yuhe Liang, and Lin Chen, and Xiangdong Wang, and Ruohuang Si, and Kunpeng Qu, and Zebin Jiang, and Bingqiang Ma, and Changfeng Miao, and Jing Li, and Bin Wang, and Peng Gao
January 2019, Cancer management and research,
Copied contents to your clipboard!